GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Net Income From Continuing Operations

Concord Biotech (BOM:543960) Net Income From Continuing Operations : ₹4,126 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Concord Biotech's net income from continuing operations for the six months ended in Mar. 2024 was ₹2,318 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₹4,126 Mil.

Concord Biotech Net Income From Continuing Operations Historical Data

The historical data trend for Concord Biotech's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Net Income From Continuing Operations Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Net Income From Continuing Operations
2,136.38 3,127.20 2,375.18 3,220.13 4,125.65

Concord Biotech Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial - 938.63 2,281.50 1,807.41 2,318.24

Concord Biotech Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹4,126 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech (BOM:543960) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Net Income From Continuing Operations
Comparable Companies
BOM:540701 BOM:543434 NSE:ZOTA BOM:531349 NSE:BALAXI BOM:500259 BOM:524717 BOM:532890 BOM:540679 BOM:524663 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CONCORDBIO:India
Address
Iscon Cross Road, S.G. Highway, 16th floor, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Website
https://www.concordbiotech.com
Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Concord Biotech (BOM:543960) Headlines

No Headlines